JTCS Concomitant Website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ichinari, H.
Right arrow Articles by Koga, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ichinari, H.
Right arrow Articles by Koga, Y.

J Thorac Cardiovasc Surg 1996;112:300-305
© 1996 Mosby, Inc.

CARDIAC AND PULMONARY REPLACEMENT

EFFECTS OF PORTAL VENOUS INOCULATION WITH DONOR SPLENOCYTES ON LUNG ALLOGRAFT SURVIVAL IN DOGS

Hideki Ichinari, MD, Tetsuya Shimizu, MD, PhD, Makoto Yoshioka, MD, PhD, Yasunori Matsuzaki, MD, PhD, Koichiro Shibata, MD, PhD, Yasunori Koga, MD, PhD

From the Second Department of Surgery, Miyazaki Medical College, Miyazaki, Japan.

Received for publication May 18, 1995 Accepted for publication Oct. 3, 1995. Address for reprints: Hideki Ichinari, MD, The Second Department of Surgery, Miyazaki Medical College, 5200 Kiwara, Kiyotake, Miyazaki 889-16, Japan.

Abstract

The effects of portal venous inoculation with donor splenocytes on lung allograft survival were evaluated in dogs. Within the dose range examined, portal venous inoculation with donor splenocytes alone did not affect the graft survival time. Although the mean graft survival time was prolonged by FK 506 treatment for 14 days, the transplanted lungs were rejected within 12 days after termination of FK 506 administration. However, when the recipients were given portal venous inoculation with donor splenocytes at the time of transplantation, the graft survival time after termination of FK 506 administration was significantly prolongated. In the recipients that received combined therapy of portal venous inoculation with donor splenocytes and FK 506 treatment, arterial oxygen tension and histologic architecture of the transplanted lungs remained within the normal range for a longer period than these measures did in control animals that received FK 506 treatment alone. Dose-response experiments revealed that 1 x 108cells/recipient was most effective in causing prolonged graft survival after termination of FK 506 treatment. On the basis of these results, perioperative portal venous inoculation with donor splenocytes can enhance the immunosuppressive effect of FK 506 in the canine lung transplantation model. (J THORACCARDIOVASCSURG1996;112:300-5)






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1996 by The American Association for Thoracic Surgery.